Note: Ingredients listed on restricted chemical lists
EC/CAS
54-64-8
Name of the chemical
Sodium o-(ethylmercurithio)benzoate
Concentration
N/A
General Information
Revision date
2008-02-08
Product name
Calvenza 03 EIV/EHV (Killed Virus)
Chemical name
Vaccine
CAS No.
Mixture
1.2.1 Relevant identified uses
For the vaccination of healthy,
Manufacturer Name
Boehringer Ingelheim Vetmedica, Inc
Icons in SDS
Company Information
company name
Boehringer Ingelheim Vetmedica, Inc
GHS Information
Signal word
WARNING!
Section 2
SECTION 2: Hazards identification
OSHA Regulatory Status Emergency Overview Physical State: Suspension of inactivated virus supplied in high density plastic bottles. Color: Opaque Odor: No data available WARNING! For use in horses only. Not for human use. Allergic reactions can occur.
Precautionary statements
Accidental human injection may cause serious local reactions or anaphylactic reaction and systemic effects. Keep only in original container. Keep at a temperature between 2 - 7° C. Do not freeze. Fire-fighting: Use foam, carbon dioxide, dry powder and water fog or material appropriate for surrounding fire. Avoid contact with eyes, skin and clothing. Wash thoroughly with soap and water after handling. Wear suitable gloves and eye/face protection. Spills: Cover with absorbent or contain. Collect and incinerate. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Have the product container or label with you when calling a poison control center or doctor, or going for treatment. If swallowed, seek medical advice immediately and show this container or label. This material and its container must be disposed of in a safe way. Keep out of reach of children. Keep away from food, drink, and animal feedstuffs. Description: Recommended for the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory disease caused by equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4), and by equine influenza virus types A2 North American and A2 Eurasian. Shake well before use. Use entire contents when first opened. Using aseptic technique, inoculate horses intramuscularly with a 2 mL dose. Administer a second 2 mL dose intramuscularly in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks by either the intramuscular or intranasal route. Revaccinate annually and prior to anticipated exposure, by either the intramuscular or intranasal route. Acute effect: Rarely, severe allergic reactions may occur that require immediate veterinary care. Antidote: Epinephrine. Precautions/Contraindications: Do not vaccinate within 21 days before slaughter. Overdosage: None known. ADVERSE REACTIONS TO PRODUCT: Anaphylactoid reactions may occur following use.
Potential health effects
Inhalation: Not expected to be an inhalation hazard with prescribed use. Eye Contact: Not expected to be a hazard to the eye with prescribed use. Exposure to liquid in eye may cause mild transient eye irritation. Skin Contact: Not expected to be a hazard to the skin. Can cause hypersensitive reactions. May cause skin sensitization by contact. Ingestion: Not expected to be an ingestion hazard with prescribed use. Ingestion may cause nausea and systemic effects. Injection: Swelling at injection site may occur.
Potential chronic health
Possible hypersensitization (development of abnormal sensitivity) Target Organ(s): Cardiovascular system, respiratory system, skin Potential Physical Effects: Can cause skin sensitization. OSHA Regulatory Status: Nonhazardous
Environmental hazards
No data available